RIGERNA
Latest round
- Angel
Last raised
- Oct 2024
Total raised
- $14M
Investors
- 5
About RIGERNA
, trading as RIGERNA, is a nucleic acid pharmaceutical company focusing on the research and development of small nucleic acid drugs. In 2022, the company acquired Zhongguancun High-tech Enterprise Certificate. In August 2024, the company's liver-targeted siRNA drug pipeline RG002C0106 for complement C3 has obtained clinical approval in Australia and China. The Company has three major platforms which are RIHOST®, RICMO® and LICOD®. Ricmo® focuses on improving accounting drug activity and improving off target effects. The company generates revenue by developing small nucleic acid drugs.
Who invested in RIGERNA
5 investors across 1 round
See all investors in RIGERNA
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Angel
Oct 21, 2024
Amount
$14M
Investors
Questions about RIGERNA
Who invested in RIGERNA?
RIGERNA has 5 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has RIGERNA raised?
RIGERNA has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did RIGERNA last raise money?
RIGERNA's most recent round on record is a Angel, in Oct 2024.
What does RIGERNA do?
, trading as RIGERNA, is a nucleic acid pharmaceutical company focusing on the research and development of small nucleic acid drugs.
Where is RIGERNA headquartered?
RIGERNA is headquartered in Suzhou, China.
Which VCs invest in companies like RIGERNA?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Peak XV Partners, MPCi and Luminous Ventures back biotechnology companies at RIGERNA's stage. Their profiles are linked below.
VCs backing biotechnology startups at Angel
Raising like RIGERNA? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.